Success story

Innovative drug to help in COVID-19 rehab

27 Aug '21
JSC Organika (Novokuznetsk) and LLC Proton (group of companies IFAR, Tomsk) in July received permission from the Ministry of Health of the Russian Federation to conduct phase II clinical trials of an innovative antithrombotic drug. The joint development is aimed at solving the problem of thrombosis in cardiological practice.

The project is being implemented with the support of the Ministry of Industry and Trade of the Russian Federation within the framework of the Pharma 2020 state program and the Skolkovo innovation center.
At present, the first in the class antithrombotic drug is being created, said in the Organika company. The fact that it affects a new molecular target, soluble guanylate cyclase, opens up new prospects for the prevention and treatment of thrombosis. Research is already beginning in the medical centers of Tomsk, Kemerovo, Novosibirsk, and further, in the final III phase, will be carried out in other cities of the country.
Phase II works should be completed by the end of 2022 of the year. In parallel, preclinical studies are being conducted, revealing new directions for the use of this drug. One of them is the treatment and rehabilitation of patients with COVID-19, since the virus provokes thrombosis of the vessels of the lungs and other vital organs, which can lead to disability and death.

According to Tomsk scientists, the drug being developed is potentially capable of limiting the development of endothelial dysfunction - the primary stage in the pathogenesis of not only thrombotic lesions, but also disruptions in the functioning of most systems for maintaining homeostasis of the body. Preparations are underway for clinical trials of the drug for this indication, including in patients with COVID-19.

In addition to preclinical and clinical studies, the industrial production of a new drug is being prepared at the chemical and pharmaceutical enterprise JSC Organika in Novokuznetsk.
This is a unique case when a domestic enterprise will carry out not only the final stage of developing a dosage form of an innovative drug patented by domestic developers, including abroad, but also synthesize a pharmaceutical substance from available raw materials, emphasized in the company. - The launch of the drug on the market is scheduled for 2025 .
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations:

Tags: covid 19 (52) /

Latest News:
27 Jan '22 | Technology & innovation
19 Nov '21 | Technology & innovation
19 Nov '21 | Technology & innovation
17 Nov '21 | Technology & innovation
 

Feature stories

27 Dec '21
An innovative hybrid plate for cranial defects...
24 Nov '21
Cerebral vascular disorders are responsible for a...
8 Oct '21
Chemists at the St. Petersburg State University...
Search (News archive - 22917)
Technology Scouting Solutions For Industry
NATT
Advertising
Marchmont News

Latest News

27 Jan '22
Siberian scientists have developed new hybrid...
26 Jan '22
K-Sky, an IT developer from northwestern Russia, is...
20 Jan '22
A research team at the Samara Polytechnic University...

Most read stories from last week

26 Jan '22
K-Sky, an IT developer from northwestern Russia, is...
26 Jan '22
The Perm-based company Where are My Children has...
27 Jan '22
Siberian scientists have developed new hybrid...